This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Nevro (NVRO) Q3 Earnings Top Estimates, FY23 Revenue View Up
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in the third quarter, owing to robust domestic performance.
Cencora (COR) Q4 Earnings Top, GLP-1 Drugs Boost Sales
by Zacks Equity Research
Cencora's (COR) fourth-quarter fiscal 2023 results benefit from overall market growth, including rising demand for GLP-1 drugs approved for diabetes and weight loss. Inflationary pressure remains.
Exact Sciences (EXAS) Q3 Earnings Beat, Gross Margin Rises
by Zacks Equity Research
Exact Sciences' (EXAS) Screening revenue upside is primarily attributable to broad-based momentum in Cologuard adoption.
Baxter (BAX) Beats on Q3 Earnings, Divests BioPharma Business
by Zacks Equity Research
Baxter (BAX) reports better-than-expected third-quarter earnings and sales. The company completes the divestment of its BioPharma Solution business. It starts reporting under a new operating model.
DENTSPLY SIRONA (XRAY) Beats on Q3 Earnings, Lowers '23 Guidance
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q3 revenues are driven by a rise in demand for aligners and CAD/CAM in the United States and a recovery in demand in China. Challenging macro headwinds linger.
Glaukos (GKOS) Q3 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Glaukos' (GKOS) third-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.
McKesson (MCK) Beats on Q2 Earnings, Raises '23 EPS View
by Zacks Equity Research
McKesson's (MCK) second-quarter fiscal 2024 results benefit from growth in the United States. Divestment hurts the International segment.
CVS Health (CVS) Q3 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Robust sales growth across all three operating segments drove CVS Health's (CVS) third-quarter results.
PacBio (PACB) Tops on Q3 Earnings, Raises FY23 Revenue View
by Zacks Equity Research
PacBio (PACB) witnesses strong revenue growth in the third quarter, partly aided by customers' continued product transition to the Revio system.
Ecolab (ECL) Q3 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Ecolab's (ECL) robust performance across all segments drives its third-quarter sales despite business challenges.
ITGR or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
Why Integer (ITGR) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Integer Holdings (ITGR) Q3 Earnings Top Estimates, FY23 View Up
by Zacks Equity Research
Integer Holdings' (ITGR) third-quarter results reflect robust Medical Sales, along with strength in the majority of the product lines.
Integer (ITGR) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 20.95% and 8.71%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks to Watch for Earnings on Oct 26: WST, DXCM & More
by Debanjana Dey
MedTech companies' Q3 results are likely to reflect strength in customer demand. Let's see how WST, DXCM, MMSI and ITGR are placed ahead of their earnings releases.
Revvity's (RVTY) New Tie-Up to Boost NGS Research Workflow
by Zacks Equity Research
Revvity's (RVTY) latest partnership is likely to address the workflow-related challenges faced by labs and democratize genomic sequencing.
3 Reasons to Add Integer Holdings (ITGR) Stock to Your Portfolio
by Zacks Equity Research
Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.
QuidelOrtho (QDEL) Reports Solid Preliminary Q3 Revenues
by Zacks Equity Research
QuidelOrtho's (QDEL) revenue growth in the third quarter is likely to have been boosted by continued strength in its non-respiratory product sales.
Merit Medical's (MMSI) New Launch to Expand Its Product Suite
by Zacks Equity Research
Merit Medical's (MMSI) latest addition to its Vascular portfolio is expected to significantly improve patient outcomes.
ITGR vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Masimo's (MASI) LiDCO to Boost Hemodynamic Monitoring Post CE Mark
by Zacks Equity Research
Masimo's (MASI) LiDCO is likely to offer clinicians a BIC solution designed to provide a more complete picture of oxygen delivery.
3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.
Veradigm (MDRX)-FDB Vela to Enhance Pharmacy Connectivity
by Zacks Equity Research
Veradigm's (MDRX) latest progress with FDB Vela is likely to offer prescribers and patients greater choice and cost transparency.